Following a resubmission:
rimegepant (Vydura®) is accepted for restricted use within NHSScotland.
Indication under review: for the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.
SMC restriction: for patients with episodic migraine who have at least 4 migraine attacks per month, but fewer than 15 headache days per month and who have had prior failure on three or more migraine preventive treatments.
In one double-blind, randomised, phase II/III study, there was a significantly greater reduction in the mean number of migraine days per month from the observation period to the last 4 weeks of the 12-week double-blind treatment period in patients treated with rimegepant compared with placebo.
Download detailed advice815KB (PDF)
- Medicine name:
- rimegepant (Vydura)
- SMC ID:
Preventive treatment of episodic migraine in adults who have at least 4 migraine attacks per month.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Central nervous system
- Submission type
- Date advice published
- 11 September 2023